In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cipla Of India Markets Generic of Bayer's Kidney Cancer Drug

This article was originally published in PharmAsia News

Executive Summary

India's Cipla has launched at home a generic version of Nexavar (sorafenib) marketed by Germany's Bayer to treat kidney cancer

You may also be interested in...

Sharing "Schering" Link Gets Bayer And Cadila To Talk Joint Venture; Deal Spanning Market To Manufacturing Likely In Final Stages

MUMBAI - Germany-headquartered agrichemicals-to-healthcare behemoth Bayer is talking to India's Cadila Healthcare to form an equal stake joint venture that will revolve around selling its own branded and generic products as well as contracting out a significant part of its manufacturing requirements

Abbott Launches Five-Minute POC Rapid COVID-19 Test

Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.

In A Bizarre Move, Trump Orders GM To Make Ventilators – Even Though The Auto Giant Already Is

President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts